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Introduction: Hemiplegic shoulder pain (HSP) is the most common pain disorder after
stroke with incidence estimates of 30–70% and associated with reductions in function,
interference with rehabilitation, and a reduced quality of life. Onset may occur as soon
as a week after stroke in 17% of patients. Management of HSP represents a complex
treatment pathway with a lack of evidence to support one treatment. The pain has
heterogeneous causes. In the acute setting, decreased range of motion in the shoulder
can be due to early-onset spasticity, capsular pattern stiffness, glenohumeral pathology,
or complex regional pain syndrome (CRPS). As contracture can form in up to 50%
of patients after stroke, effective management of the painful shoulder and upper limb
with decreased range of motion requires assessment of each possible contributor for
effective treatment. The anesthetic diagnostic nerve block (DNB) is known to differentiate
spasticity from contracture and other disorders of immobility and can be useful in
determining an appropriate treatment pathway.
Objective: To create a diagnostic algorithm to differentiate between the causes of HSP
in the stiff, painful shoulder in the subacute setting using diagnostic techniques including
the Budapest Criteria for CRPS and DNB for spasticity and pain generators.
Results: Examination of each joint in the upper extremity with HSP may differentiate
each diagnosis with the use of an algorithm. Pain and stiffness isolated to the shoulder
may be differentiated as primary shoulder pathology; sensory suprascapular DNB
or intra-articular/subacromial injection can assist in differentiating adhesive capsulitis,
arthritis, or rotator cuff injury. CRPS may affect the shoulder, elbow, wrist, and hand and
can be evaluated with the Budapest Criteria. Spasticity can be differentiated with the
use of motor DNB. A combination of these disorders may cause HSP, and the proposed
treatment algorithm may offer assistance in selecting a systematic treatment pathway.
Keywords: muscle spasticity, complex regional pain syndromes, bursitis, stroke, rehabilitation
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INTRODUCTION
Hemiplegic shoulder pain (HSP) is the most common pain
disorder after stroke and one of the four most common
complications. The estimated incidence ranges from of 30–70%
(1–3). HSP is associated with reductions in function, interference
with rehabilitation efforts (4), and a reduced quality of life (5).
Onset of HSP is rapid, occurring as soon as a week after stroke
in 17% of patients (6). While HSP is ubiquitous (1, 7), the
management of HSP represents a complex treatment pathway
with insufficient evidence supporting one particular treatment
(8). It is known that permanent loss of range of motion (ROM)
can occur within 3–6 weeks, and according to the 2019 Canadian
Stroke Best Practice Recommendations (CSBPR), there is a lack
of evidence supporting individual treatments (9).
The pain associated with HSP may be due to heterogeneous
causes. In the acute setting, decreased ROM in the shoulder
may represent several processes including the early onset of
spasticity, capsular pattern stiffness, glenohumeral pathology,
or a component of complex regional pain syndrome (CRPS)
known as the post-stroke shoulder hand syndrome. Effective
management of the HSP with decreased ROM requires
assessment of each possible contributor (3). Multiple factors
contribute to normal shoulder positioning and function. Proper
shoulder positioning involves a stabilized glenohumeral joint
(actively and passively), appropriate glenoid fossa angle, and
correct scapular and vertebral column alignment (10). The
suprascapular nerve is not only vital to motor function, it
provides up to 70% of the sensory fibers to the shoulder (11,
12), and pain transmitted by the suprascapular nerve represents
another potential underlying cause of HSP (13).
The pathology attributed to HSP includes a variety of
neurological and mechanical factors, and effective treatment
is heavily influenced by accurate and early detection of these
factors. The lack of early recognition of the causative pathology
of HSP can lead to worsening limb function and increased pain
and may impair the rehabilitation and recovery process, as the
pain may peak at up to 4 months (3, 14, 15). Early intervention
may reduce the risk and onset of contracture, which can lead
to significant impairments and a reduced quality of life (15–
17). The incidence of developing at least one contracture in
stroke patients within 6 months of their stroke is estimated
at 52% (18). Contractures are a source of pain and limited
ROM, limit function (18, 19), and require intensive treatment,
as stretching has not shown to be clinically effective (20).
Patients with contractures and limited volitional control of their
shoulder muscles, adduction, or internal rotation can experience
maceration, skin dehiscence, impaired axillary hygiene, and
difficulty dressing (21, 22). For these patients, relief of the
contracture and an improvement of passive function may require
surgery (shoulder tenotomies) to release the pectoralis major,
latissimus dorsi, teres major, and subscapularis muscles (21).
The use of diagnostic nerve blocks (DNBs) in the assessment
of spasticity has gained renewed attention. Sensory DNB may
increase ROM and reduce spasticity through the reduction of
pain (23, 24), while motor DNB has a more direct impact on
temporarily reducing spasticity by paralyzing the targeted nerve
branch to a muscle (25). Tardieu and Hariga (26) first described
the use of DNB for spasticity in 1964. DNBs have proven to
be effective at differentiating between spastic hypertonia, joint
stiffness, and contracture (27). DNBs can be used to predict how
a patient will respond to local chemodenervation with botulinum
toxin (BoNT) or phenol/alcohol. A DNB will cause a spastic
muscle to relax to its maximal length, whereas a contracture will
have minimal or no change.
Despite the importance of early diagnosis and intervention,
few guidelines exist to systematically direct early care. There
is a lack of validated and reliable instruments to assess pain
associated with arm spasticity (28). Management of HSP has been
proposed in many review articles, which includes management of
the flaccid or subluxed shoulder. Guidelines, such as the CSBPR,
present the evidence for treating the individual pathologies that
result in HSP; however, there is no current clinical pathway
to assist the clinician in identifying the causative pathologies
and how to treat the contribution of each pathologic process.
The new onset of HSP presents additional diagnostic challenges
due to patient-specific factors, such as decreased levels of
arousal, language disorders, weakness, limited exercise tolerance,
medical comorbidities, and sensory and visual–spatial neglect.
Furthermore, HSP with reduced ROM may not be isolated
and may be accompanied by stiffness, pain, and reduced
ROM in the distal upper extremity joints. Thus, the ability to
accurately differentiate between the causes of painful reduced
ROM, including isolated shoulder pain, CRPS, spasticity, and
contracture requires a method to differentiate the etiologies.
In the absence of an established clinical pathway, we have
drawn on our own use of the clinical evidence, such as prednisone
for the treatment of CRPS (29), the use of motor DNB for
spasticity assessment, suprascapular DNB for isolated shoulder
pain (13, 30, 31), and early intervention for spasticity (32). We
propose an algorithm to assist in the assessment andmanagement
of new-onset HSP in shoulders with stiffness and a reduced ROM
built from our own clinical experience in treating this condition.
We propose a clinical and interventional pathway, the ViVe
Algorithm, to assess each component and guide the treatment of
each condition.
METHODS
The development of the ViVe Algorithm involved a pathway
created from knowledge gained through routine clinical care of
HSP at one site in Canada and one in Italy. Both senior authors
have extensive clinical experience in treating new-onset HSP.
This includes international collaboration in early assessment
and treatment of spasticity (32). Both clinicians have experience
and publications in ultrasound-guided DNB. Additionally, the
authors have a routine clinical practice and publications in
either suprascapular DNB or the assessment and treatment of
CRPS. The algorithm is thus a joint collaboration of our routine
care that recognizes the clinical challenges in the treatment of
new-onset HSP. Development of the algorithm required the
involvement of the multidisciplinary rehabilitation teams. It is
essential to underscore that nursing, physical, and occupational
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therapists are key players who continually assess and report on
the development of HSP. The foundation for the algorithm is in
the assessment and feedback from the therapy teams that report
on pain, ROM, and presence of symptoms of CRPS, spasticity,
and contracture. In turn, the components of the ViVe Algorithm
were created based on the signs and symptoms identified by
the therapy teams and the diagnostic uncertainties that arose
in consultation with the physician/therapy teams. In contrast
to the traditional approach, our algorithm was created through
collaborative assessment of each joint in the upper extremity to
assess the etiology of its limited and painful ROM. The DNB
facilitates that differentiation.
A literature review of the anatomy, assessment, and treatment
of isolated shoulder pain, CPRS, and spasticity was conducted.
Sample illustrative case studies were created to illustrate the
pathways of the algorithm, with a guide to the clinical
examination and diagnostic procedures.
When it is unclear if decreased ROM is due to isolated
shoulder pain, CRPS, or spastic muscle overactivity, DNBs are
implemented. Suprascapular sensory nerve blocks are performed
for isolated shoulder pain along with intra-articular injections
(Figure 2).
The presence of CRPS is assessed using the Budapest Criteria
with guidance from the CSBPR. Treatment with prednisone was
offered for the CRPS using recommended doses (29, 33).
To assess the contribution of spastic muscle overactivity,
we implemented the lateral pectoral nerve (LPN) block as
the primary DNB for the adducted shoulder (Figure 3).
Musculocutaneous (MSCN) DNBs to the brachialis, biceps, and
the radial nerve to the brachioradialis are utilized for the spastic
flexed elbow (25). Radial and median nerve blocks are for the
wrist and fingers.
The DNB is performed by the infiltration of small volumes (1–
4ml) of a 2% lidocaine around a nerve or nerve fascicle to select
the most responsible muscles in a spastic deformity (25, 34, 35).
To assist localization, we recommend that they are performed in
combination with e-stimulation and ultrasound (30, 31).
Isolated pain in the shoulder or other joints is assessed, and
other causes of joint inflammation, arthropathy, or heterotopic
ossification are ruled out by clinical judgment and testing,
including diagnostic imaging of the shoulder as indicated.
The patient’s active range of motion (AROM) and passive
range of motion (PROM) are evaluated for spasticity and
measured using the Modified Ashworth Scale (MAS) and
Modified Tardieu Scale (MTS). For CRPS, the presence or
absence of the signs and symptoms of the Budapest Criteria
is utilized.
RESULTS
The ViVe Algorithm was developed to allow characterization of
the stiff hemiplegic shoulder with and without involvement of the
distal upper extremity joints (Figure 1). It was designed for the
post-acute state when spasticity, CRPS, and capsulitis typically
first develop.WhenHSP is first identified, the algorithm next asks
if elbow, wrist, or fingers are involved. If not involved, isolated
shoulder pain, such as capsulitis is suspected. In the absence
of apparent spasticity or pectoral contracture, treatment is for
isolated shoulder pain, including capsulitis; suprascapular DNB
and intra-articular injections are offered. If capsulitis is uncertain,
then a DNB of the LPN to assess for spasticity is performed. If
ROM improves, then spasticity is presumed present and treated
as such. If not, capsulitis is again suspected, but joint pathology,
heterotopic ossification, and contracture should be ruled out
through medical imaging and palpation of contracted tendons.
If the elbow, wrist, or fingers are involved, an assessment
with the Budapest Criteria for CRPS is performed as well as
an assessment for the presence of spasticity. If the criteria are
met, treatment with oral prednisone is recommended initially. If
differentiation between spasticity and CRPS is uncertain, a DNB
of the MSCN and/or radial nerves is performed for the elbow
and potentially the median and/or ulnar for the wrist and fingers.
Significant improvements in ROM after the DNBs suggest that
the cause of the restricted ROM is spasticity. If there is no
improvement, early contracture, joint deformity, and heterotopic
ossification are to be ruled out. The algorithm is designed to be
revisited after each treatment.
Illustrative Composite Cases
Case 1
A patient in their 80s presented with dense right hemiplegia due
to a left frontal subcortical infarct. The right arm was flaccid
initially. There was no history of prior shoulder pain. At 2 weeks
post-stroke assessment, the algorithm found reduced painful
PROM involving the shoulder, elbow, wrist, and fingers. At 3
weeks, the therapy team noted that the left hand and wrist were
swollen and painful with brawny skin; they were shiny and warm.
The limb met the Budapest Criteria for CRPS in the wrist and
hand with minimal joint movement in the painful wrist and
fingers. The presence of spasticity was assessed. The elbow had
reduced extension with an initial fast spastic catch or V3 at
90◦ and maximal slow ROM or V1 of 160◦ on the MTS and a
MAS grade of 2. The shoulder abduction was up to 90◦, limited
by pain, thus spasticity could not be properly assessed, though
a taut band was felt in the pectoralis muscles with abduction.
A decision to first treat the CRPS was made due to the whole
limb involvement. Here, 60mg of prednisone was started with
a daily taper (33). Within 5 days, the swelling in the hand
resolved, passive manipulation was possible due to reduced pain.
The temperature and discoloration normalized. There was mild
stiffness, but no spasticity in the hand or wrist. The algorithm
was re-implemented to assess the ongoing elbow and shoulder
reduced ROM. The MAS remained 2 at the elbow and was now 2
with shoulder abduction. A DNB was performed to both the LPN
and MSCN branch to the brachialis. This resulted in full PROM
in both elbow and shoulder and a drop in MAS grade to 1+. The
cause of the reduced ROMwas determined to be due to spasticity.
Then, 150 units of onabotulinum A (BoNT) were injected (50
units to the pectoralis, 60 units to the brachialis, and 40 units
to the brachioradialis with ultrasound guidance). At 2 weeks’
follow-up, there was no reported pain and increased PROM in
the wrist and fingers. At 3 months, PROM was full in the elbow
and shoulder with some active antigravity movements. There was
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FIGURE 1 | ViVe treatment algorithm.
no active movement in the fingers, but they were pain-free with
full ROM.
Case 2
A patient in their 70s suffered a large subarachnoid bleed. There
was no known prior history of shoulder pain. At 3 weeks, the
examination found a painful capsular pattern to the shoulder,
with passive abduction to 70◦. A MAS grade of 2 was noted
in the elbow flexors, which had a V3 of 110◦ and V1 of 170◦.
There was a spastic catch and release in the limited shoulder
ROM, with a taut band in the pectoralis muscle noted, but the
presence of pain made it challenging to measure. There were no
features of CRPS. Using the algorithm, a diagnosis of isolated
shoulder pain, with early capsulitis, was made in the presence
of spasticity. A glenohumeral cortisone injection with 40mg of
Depo-Medrol and 4 cc of 2% lidocaine with ultrasound guidance
was performed, as well as a guided suprascapular DNB with 2
cc of lidocaine. At 15min, the shoulder pain was significantly
diminished, and PROM had improved by 30◦, but spasticity was
unmasked to reveal MAS of 2 in the shoulder. On day 4, the
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pain was improved but spasticity remained. Using the algorithm,
150 units of BoNT were administered to the elbow flexors and
shoulder adductors (brachialis, brachioradialis, and pectoralis
muscles). Muscle tone continually improved over the course of 1
month, and there was full PROM of the shoulder and elbow with
MAS grade of 1. No further treatment was required long-term.
Case 3
A patient in their 50s presented with left hemiplegia due to a right
frontal lobe infarct. Within 5 days, there was left arm weakness
with spasticity of MAS grade of 3 isolated to only the elbow
flexors. There was no reported shoulder pain. There were active
movements with gravity eliminated in the elbow and strong
finger flexors. Treatment was offered with a total of 125 units
BoNT to the brachialis and brachioradialis. At 1 month, ROM
at the elbow had greatly improved, both actively and passively
with a MAS of 1, with no V3, and a full V1 of 180◦. At 3
months, as an outpatient, there was now a painful stiffness in
the shoulder, limiting abduction and external rotation to < 90◦.
Using the algorithm, it was notable that elbow flexor tone was
normal, and the wrist and hand remained unaffected. No taut
band was felt in the pectoralis muscle when the shoulder was
passively abducted. There were no features of CRPS. It remained
unclear if this was isolated shoulder pain or spasticity. A DNB of
the LPN was performed. The pectoral muscles went flaccid post-
injection, but no change in ROM occurred. Using the algorithm,
a glenohumeral cortisone injection with a suprascapular DNB
was performed, and the pain immediately improved, but minimal
improvement in shoulder ROM was noted. An intra-articular
cortisone injection was declined by the patient. A diagnosis
of adhesive capsulitis was made. At 1 year post-stroke, active
movements in the whole limb were graded from 4 to 5 (MRC),
and spasticity was not detectable in the limb. The left shoulder
ROM was improved with little pain, but there remained a mild
capsular restriction.
DISCUSSION
The ideal management of HSP remains elusive. Patients typically
receive focal intensive therapies in the initial months after a
stroke, along with inpatient and outpatient therapies. A 2021
review found that 9.4% of patients with paresis will develop
severe or disabling spasticity (36). Hefter et al. (37) noted
that four of the five most common spasticity patterns in the
upper extremity include adduction and internal rotation of the
shoulder. Kwah et al. (18) demonstrated that of 200 consecutive
patients, 25% of all stroke patients and 38% of moderate to severe
stroke patients developed a shoulder contracture within 6months
(22 and 35% for elbows, 13 and 29% for wrists, respectively).
Early intervention to prevent contracture development and
disuse is the goal of post-stroke spasticity (PSS) care. Deltombe
et al. (35) demonstrated the role of DNBs in differentiating
spasticity from contracture in the foot and offered an elegant
algorithm to guide the clinician. The post-acute HSP offers an
additional diagnostic challenge due to frequency of CRPS and
capsulitis in addition to the spasticity. Accurate assessment is
additionally complicated by the possibility that CRPS, adhesive
capsulitis, and spasticity may all be actively developing. Hence,
the need for an algorithm to reflect this time dependence
and heterogeneity.
The shoulder hand syndrome after stroke is a well-described
variant of CRPS (38, 39), with an estimated incidence of up
to 48.8% in the first 28 weeks (14). Risk factors include motor
disability and trauma related to altered shoulder biomechanics.
The two major types of CRPS (CRPS types I and II) are
characterized by the presence or absence of an identifiable
nerve injury. CRPS type I is not limited to an individual
peripheral nerve and is associated with edema, skin blood flow
abnormalities, and sudomotor activity in the region of the pain in
the form of both allodynia and hyperalgesia. CRPS type II occurs
after injury to a nerve or a major nerve branch innervating a
particular region and causes a characteristic burning sensation in
addition to allodynia and hyperpathia within the region. Clinical
diagnosis is assisted by the patient’s medical history and assessed
by clinical examination using the Budapest Criteria (40, 41).
Kalita et al. (42) proposed an assessment of post-stroke CRPS
based on the work of Braus et al. (43).
The CSBPR offer that the diagnosis should be based
on clinical findings including pain and tenderness of the
metacarpophalangeal and proximal interphalangeal joints and
can be associated with edema over the dorsum of the fingers,
trophic skin changes, hyperesthesia, and limited ROM as level
C evidence (9). When clinical diagnosis is unclear, the most
commonly used imaging modalities to assist diagnosis are triple-
phase bone scans, which detect the characteristic increased
periarticular uptake in the distal joints (44, 45).
Altas et al. (46) examined the risk factors and clinical
treatment parameters associated with post-stroke CRPS and
concluded that the nociceptive and neuropathic pain etiologies
encompassed by CRPS complicate treatment, and optimal
treatment often requires a combination of treatment modalities.
These can include pharmacological, orthotic, biomechanical,
and electrophysiological therapies. In a review of the current
CRPS literature, Van Eijs et al. (47) emphasized prioritization
of pharmacological pain management and physical rehabilitation
of limb function, noting they should be started as early as
possible, while interventional pain management techniques are
only considered when there is no improvement to limb function
or pain.
A number of analgesic and anti-inflammatory
pharmacological treatments have been assessed for efficacy
in managing CRPS, including bisphosphonates, calcitonin, and
corticosteroids. Corticosteroids are commonly used to treat
CRPS post-stroke; a 1994 study showed 31 out of 34 post-stoke
patients who developed CRPS achieved near-total relief within
an average of 10 days following corticosteroids (43). Two studies
by Kalita et al. (29, 42) demonstrated the viability of prednisolone
(40mg), as 89.7% of patients with post-stroke CRPS experienced
an improvement in their symptoms following 1–2 months of
treatment. Continuation of a lower dose of prednisolone (10mg)
for an additional 2 more months resulted in no recurrence
of CRPS and continual improvement, whereas 50% had a
recurrence when prednisolone treatment was stopped. Patients
who discontinued treatment after 2 weeks had deterioration at
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1 month and required reinstitution of prednisolone, following
which 77% of them saw CRPS improvement within the next
month, emphasizing the importance of monitoring the patients
for resolution (29). The CSBPR affords prednisone as a treatment
of CRPS as Level B evidence (9). The presence of CRPS severely
compromises clinical assessment of spastic muscle overactivity
due to the effects of pain with the movement of multiple joints;
therefore, CRPS should be rapidly assessed and treated.
Post-stroke HSP has been attributed to rotator cuff disease,
adhesive capsulitis, and spasticity subluxation (1, 7). It is
important to rule out preexisting causes or common causes
such as rotator cuff tendinopathy or osteoarthritis, as well
as acquired plexus or lower motor traction injuries from the
handling of the hemiplegic shoulder (48, 49). There is evidence
showing that swollen suprascapular nerves might be related to
painful shoulders in the aging population (50). Resistance to
movement commonly coincides most with both capsulitis and
spastic muscle overactivity.
Both the suprascapular DNB and intra-articular
corticosteroids are shown to decrease pain and improve
ROM in HSP (1, 7, 13, 51, 52) (Figure 2). Either intervention
is readily accessible to clinicians providing care and may assist
in distinguishing the contributions of pain vs. spastic muscle
FIGURE 2 | Suprascapular nerve block.
overactivity. Intra-articular injections with anesthetics and
DNB allow one to immediately assess if capsular or joint pain
is contributing to decreased ROM, as PROM and, if possibly,
AROM are reassessed within minutes. A successful reduction of
pain with a DNB also allows the implementation of longer-lasting
nerve procedures with techniques that include phenol (53, 54) or
pulsed radiofrequency (52, 55).
Upper extremity spastic muscle overactivity has been
identified as one of the most common causes of HSP and may
appear in the acute phase (56). Regardless of the pathology,
a review found that HSP is higher than normal in patients
with PSS (57). HSP patients showed significantly more spasticity
in affected limbs compared to limbs that are pain-free (58).
Reported prevalence of PSS, most commonly assessed using the
MAS (59), ranges from 4 to 27% during the first 6 weeks after
stroke (60).
Early treatment includes physical modalities, bracing,
oral agents, and focal chemodenervation with BoNT or
phenol/alcohol. While few studies have addressed early
treatment with BoNT, the few available note that a trend
of successful early treatment is possible with reduced doses
(61–63). The most commonly targeted muscles for spasticity of
the shoulder include the pectoralis and subscapularis muscles
FIGURE 3 | Lateral pectoral nerve block.
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(53, 64–66), although consensus on which muscle to treat with
BoNT varies widely (66). Treatments of PSS related to HSP
are centered around improving arm abduction and external
rotation. In the presence of pain, the assessment of spastic muscle
overactivity may be compromised due to inability to completely
range a joint, thus as addressed previously, pain reduction is
a key first step and clinical assessment and treatment of CRPS
and isolated shoulder pain should precede assessment of spastic
muscle overactivity.
The development of PSS related to HSP may impair ROM.
The pectoralis and subscapularis muscles contribute largely to the
abduction and internal rotation of the shoulder. The pectoralis
major muscle (PMM) is primarily innervated by branches of
the brachial plexus; the MPN’s role is supplementary, whereas
the LPN’s increased thickness and muscle innervation make it
vital to proper function (67), and injury can result in total
denervation, atrophy, and fibrosis of the PMM (68). Spasticity
in the subscapularis muscles can limit shoulder abduction,
flexion, and external rotation (23). Scapular rotation can also
be impaired due to increased tone in the muscles attached
to the scapular surface (latissimus dorsi, levator scapulae,
rhomboid). These muscles surround the scapula and assist
with abduction and the external and internal rotation of the
glenohumeral joint.
As the adducted shoulder is a common painful pattern,
pectoral DNB remains a key option to distinguish between spastic
muscle overactivity and capsulitis. The PMM is the dominant
and largest muscle with clavicular, sternal, and abdominal
portions (69). The course of the nerve has been found to
be consistent in anatomical studies that demonstrate that the
LPN was found to course alongside the pectoral branches of
the thoracoacromial blood vessels on the undersurface of the
PMM in 100 consecutive patients (68) (Figure 3). The LPN was
shown to innervate both heads of the PMM (32). Targeting
the LPN may also have an effect on the pectoralis minor
muscle, as it gives innervation to this muscle through the
communicating ansa pectoralis (70). We have used the LPN
in our algorithm, as the MPN is less consistent and deeper to
access and has numerous branches (69). Unlike, the pectoral
muscles, the subscapularis cannot be palpated and has numerous
innervations; thus, DNB is not practical (71). The thoracodorsal
nerve is highly consistent in its course. The nerve can be targeted
after it enters the latissimus dorsi at a point midway along the
thorax (72).
For the elbow, the recommended targets for nerve blocks are
the branches of the MSCN nerve to the brachialis and biceps and
the radial nerve to the brachioradialis (25, 31). For the wrist and
fingers, median and ulnar nerve DNBs are performed.
Changes after motor DNB are documented by measuring
changes to the fast catch V3 and slow stretch V1 ROM on the
MTS (73). Filipetti and Decq (74) demonstrated the value of
incorporating DNBs into the treatment approach of a cohort
of 566 patients. Functional assessment was carried out using
the MTS and MAS before and after DNB administration
and determined that DNBs assisted in determining the
relative contribution of the muscle or muscles contributing to
overactivity and spasticity and muscle shortening leading to
pathologic posture. They concluded that the method’s ability in
predicting new functional balance and treatment effectiveness is
particularly valuable, and DNBs represent a necessary stage to
patient assessment (74).
This algorithm has numerous limitations. The CSBPR notes
the lack of evidence to evaluate and support any treatment
pathway for HSP. Accepted outcomes for CRPS and spasticity
are equally elusive, and there is no accepted universal outcome
yet to validate the ViVe Algorithm. In the acute to subacute
phase, weakness, flaccidity, visual and sensory neglect, and
cognitive and language deficits preclude the use of most outcome
tools. Lastly, the DNB is not universally practiced and requires
knowledge of anatomy and technique. We note that the most
up-to-date guide on DNB determined that Ultrasound (US)
has not yet been sufficiently noted be superior to anatomical
landmark, based on a paucity of literature (27). This literature is
growing (30, 34, 75).
CONCLUSION
We believe this to be the first proposed algorithm to
assess the early-phase HSP based on the presentation of
a painful limb with reduced ROM, to distinguish from
cases of flaccidity and subluxation. This algorithm is a
proposal to guide clinicians into selecting the most appropriate
diagnosis of the etiology of pain and reduction in ROM.
Each of the conditions, CRPS, capsulitis, and spasticity,
has existing treatment protocols that can used alone or in
combination. The goal of the algorithm is to ultimately
prevent irreversible contracture formation and pain from
impairing recovery in the subacute phase when patients typically
receive their most intense phase of rehabilitation. The ViVe
Algorithm allows for collaboration between physiotherapists,
occupational therapists, and spasticity physicians to develop a
treatment pathway that allows all providers to produce optimal
medical interventions.
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